Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06649331
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- NCT06649331 ↗
- Recruiting
- Fudan University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Advanced Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Breast Cancer
- Interventions
- SHR-A1811; SHR-A1921; SHR-A2009; SHR-A2102; Famitinib; Fat Module Formula for Special Medical Purposes; Trastuzumab (or biosimilar); 9MW2821; Disitamab Vedotin (RC48); Treatment of physician's choice (TPC)
- Arms
- A · Experimental
- B · Experimental
- C · Experimental
- D · Experimental
- E · Experimental
- F · Experimental
- G · Experimental
- H · Experimental
- I · Experimental
- J · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Fudan University
- Start
- Oct 21, 2024
- Primary completion
- Sep 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06649331 · updated Sep 3, 2026